Dustri Online Services

Search Results

Books: 0	Journals: 1	Articles: 1

Bioavailability Section

Pharmacokinetic and bioequivalence study of apremilast tablets in healthy Chinese subjects under fasting and fed conditions 

Pan Lu, Fang Yao, Jie Wang, Yingxia He, Jun Liang, Xuejia Zhai, and Guan Liu

Price
42.00 $

Price

42.00 $

Add to Cart ###ENGLISH_ABSTRACT_LINK### ###FREE_ENGLISH_ARTICLE_DOWNLIAD_LINK###

Volume 64 (2026) p. 487 - 497

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 64 – No. 9/2026 (487-497)

Pharmacokinetic and bioequivalence study of apremilast tablets in healthy Chinese subjects under fasting and fed conditions 

Pan Lu¹, Fang Yao¹, Jie Wang¹, Yingxia He¹, Jun Liang¹, Xuejia Zhai²#³, and Guan Liu¹

¹PhaseI Clinical Research Center, Wuhan Pulmonary Hospital, ²Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and ³Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Union Hospital, Wuhan, China
Apremilast is a pioneering oral selective phosphodiesterase-4 inhibitor for the treatment of psoriasis. To evaluate and compare the pharmacokinetic properties and bioavailability of apremilast tablets manufactured by Nanjing Haijing Pharmaceutical Company (Nanjing, China) with apremilast tablets certified by Celgene Europe B.V. (Utrecht, The Netherlands), we conducted a randomized, open-label, single-dose, two-period, crossover study in healthy Chinese subjects under fasted and fed conditions. Eligible subjects were randomly assigned to receive reference or test apremilast tablets in the first treatment period and the other formulation in the second period. Serial blood samples were collected for pharmacokinetic analysis. Adverse events were recorded. A total of 28 healthy subjects were enrolled in the fasting cohort and 36 subjects in the fed cohort. The 90% confidence intervals of the geometric mean ratios of the test to reference formulations were 91.56 – 106.18% for C_max, 96.08 – 108.18% for AUC_0–t, and 96.02 – 107.67% for AUC_0–∞ in the fasting cohort, and 95.15 – 107.05% for C_max, 105.13 – 113.45% for AUC_0–t, and 104.80 – 111.91% for AUC_0–∞ in the fed cohort, all of which were within the bioequivalence range of 80.00 – 125.00%. There were no serious adverse events. The results showed that the test and reference apremilast tablets were bioequivalent and well tolerated in healthy Chinese subjects under fasting and fed conditions.Correspondence to:
Guan Liu, MD
Phase | Clinical Research Center
Wuhan Pulmonary Hospital
Wuhan, People’s Republic of China
Email: [email protected]

Warenkorb Übersicht

Warenkorb Übersicht
Typ	Anz	Rabatt	MwSt	Preis
Der Warenkorb ist leer

Ihr Warenkorb

Search Results

Warenkorb Übersicht

Senden Sie uns eine E-Mail